VTAK stock icon

Catheter Precision

0.3255 USD
-0.0031
0.94%
At close Oct 9, 4:00 PM EDT
Pre-market
0.3600
+0.0345
10.60%
1 day
-0.94%
5 days
-10.21%
1 month
-21.49%
3 months
-91.30%
6 months
-93.68%
Year to date
-91.94%
1 year
-92.43%
5 years
-100.00%
 

About: Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System) which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.

Employees: 14

0
Funds holding %
of 6,740 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

8% more funds holding

Funds holding: 13 [Q1] → 14 (+1) [Q2]

6% more capital invested

Capital invested by funds: $389K [Q1] → $415K (+$25.2K) [Q2]

1.22% less ownership

Funds ownership: 10.58% [Q1] → 9.36% (-1.22%) [Q2]

Research analyst outlook

We haven’t received any recent analyst ratings for VTAK.

Financial journalist opinion

Based on 4 articles about VTAK published over the past 30 days

Neutral
Accesswire
1 month ago
Catheter Precision, Inc. (NYSE American: VTAK) Reports Q2 2024 Highlights and Operational Performance Report
FORT MILL, SC / ACCESSWIRE / August 14, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a MedTech company pioneering products in the growing field of cardiac electrophysiology, including its VIVO™ and LockeT product(s), releases Q2 Financials and Operational Report. Operational highlights include the following: First commercial sales of LockeT in the US 14 new sales and clinical hires at various stages of training completion Larger number of US hospitals than projected have confirmed product interest and have scheduled evaluations 23 hospitals for LockeT 10 hospitals for VIVO VIVO product evaluation started at large volume center in Italy New LockeT publication in the Journal of Cardiovascular Electrophysiology Catheter Precision is attending the Kansas City Heart Rhythm Society Conference (KCHRS) in Kansas City August 17 and 18, 2024 Completion of the VIVO EU Registry in June 2024 2024 Second Quarter Financial Results are as follows: Total assets at June 30, 2024, were $26 million Total cash on position at June 30, 2024 was $16 thousand, and $330 thousand at August 12, 2024 Total revenues for the three and six months ended June 30, 2024, were $93 thousand and $175 thousand, respectively Shareholders' equity as of June 30, 2024, was $14.3 million Net loss for the three and six months ended June 30, 2024, was ($4.2) million and ($6.9) million, respectively LockeT sales for the three and six months ended June 30, 2024, were $38 thousand for both periods.
Catheter Precision, Inc. (NYSE American: VTAK) Reports Q2 2024 Highlights and Operational Performance Report
Charts implemented using Lightweight Charts™